» Articles » PMID: 32083950

Breast Cancer Care in Jordan

Overview
Journal JCO Glob Oncol
Specialty Oncology
Date 2020 Feb 22
PMID 32083950
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancer is the most common malignancy in Jordan and the third leading cause of cancer death after lung and colorectal cancers. Although the incidence of breast cancer in Jordan is lower than that in industrialized nations, the number of new cases has been significantly increasing, and women present with breast cancer at a younger age and with more advanced disease than women in Western countries. Jordan is a medium-income country with limited resources and a young population structure. Therefore, breast cancer poses a particularly challenging burden on the country's health care system. Despite ongoing endeavors to improve breast cancer care at both public and private levels, more work is needed to achieve downstaging of the disease and improve access, awareness, and participation in early detection. Multimodality treatment facilities and supportive care are available; however, the quality of care varies widely according to where the patient is treated, and most treatment facilities remain located centrally, thus, creating access difficulties. The King Hussein Cancer Center, the only comprehensive cancer center in Jordan, has changed the practice of oncology in the country via implementation of a multidisciplinary approach to treatment, monitoring of treatment outcomes, and investments in ongoing cancer research. However, there remains no national system for ensuring provision of high-quality cancer care nationwide. Here, we review the epidemiology of breast cancer and the current status of breast cancer care in Jordan, we compare our treatment outcomes with international ones, and we highlight challenges and improvement opportunities.

Citing Articles

Characteristics of Unplanned Hospital Admissions Among Patients With Cancer Treated at a Comprehensive Cancer Center in Jordan.

Mustafa N, Attili D, Alsoud F, Alsheikh N, Faqeer N Cureus. 2025; 17(1):e77012.

PMID: 39912021 PMC: 11798342. DOI: 10.7759/cureus.77012.


Clinical Outcomes of Patients Treated with Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast Cancer, Real-World Data from a Low-Resourced Country.

Abdel-Razeq H, Sharaf B, Khater S, Baidoun H, Bani Hani H, Taqash A Immunotargets Ther. 2024; 13:501-512.

PMID: 39364228 PMC: 11448467. DOI: 10.2147/ITT.S479153.


Variations in Depression and Anxiety among Jordanian Women Undergoing Mastectomy and Reconstruction Surgery: Impact of Familial Support.

Bani-Ahmed A, Al-Baghdadi D, Hussein R, Al-Sharman A Asian Pac J Cancer Prev. 2024; 25(9):3277-3282.

PMID: 39342607 PMC: 11700329. DOI: 10.31557/APJCP.2024.25.9.3277.


Multi-Gene Panel Testing for Hereditary Cancer Predisposition Among Patients Sixty-Five Years and Above Diagnosed With Breast Cancer.

Abdel-Razeq H, Tamimi F, Sharaf B, Nielsen S, Heald B, Hatchell K World J Oncol. 2024; 15(5):777-783.

PMID: 39328331 PMC: 11424113. DOI: 10.14740/wjon1919.


Community Pharmacists' Readiness for Breast Cancer Mammogram Promotion: A National Survey from Jordan.

Gharaibeh L, Liswi M, Al-Ajlouni R, Shafei D, Fakheraldeen R J Multidiscip Healthc. 2024; 17:4475-4489.

PMID: 39308798 PMC: 11416785. DOI: 10.2147/JMDH.S471151.


References
1.
Abdel-Razeq H, Saadeh S, Abu-Nasser M, Abdulelah H, Marie L, Salam M . Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients. Onco Targets Ther. 2018; 11:2091-2096. PMC: 5905529. DOI: 10.2147/OTT.S151821. View

2.
Fitzmaurice C, Allen C, Barber R, Barregard L, Bhutta Z, Brenner H . Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2016; 3(4):524-548. PMC: 6103527. DOI: 10.1001/jamaoncol.2016.5688. View

3.
Stordeur S, Vrijens F, Devriese S, Beirens K, van Eycken E, Vlayen J . Developing and measuring a set of process and outcome indicators for breast cancer. Breast. 2011; 21(3):253-60. DOI: 10.1016/j.breast.2011.10.003. View

4.
Spronk I, Korevaar J, Schellevis F, Albreht T, Burgers J . Evidence-based recommendations on care for breast cancer survivors for primary care providers: a review of evidence-based breast cancer guidelines. BMJ Open. 2017; 7(12):e015118. PMC: 5728293. DOI: 10.1136/bmjopen-2016-015118. View

5.
Abu-Helalah A, Alshraideh H, Al-Hanaqtah M, Dana M, Al-Omari A, Mubaidin R . Delay in Presentation, Diagnosis, and Treatment for Breast Cancer Patients in Jordan. Breast J. 2015; 22(2):213-7. DOI: 10.1111/tbj.12541. View